Annual costs of rheumatoid arthritis in Turkey
Abstract Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution(SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as €2,669.14 patient/year. Outpatient costs were found to be €240.40. Routine tests during the year were calculated as €98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was €87.76. €2,238 was determined as being paid per year for medication alone (including anti-TNF) and €4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Rheumatology international - 30(2009), 5 vom: 07. Juli, Seite 637-641 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malhan, Simten [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer-Verlag 2009 |
|---|
| doi: |
10.1007/s00296-009-1040-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR003841758 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR003841758 | ||
| 003 | DE-627 | ||
| 005 | 20230519183700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-009-1040-2 |2 doi | |
| 035 | |a (DE-627)SPR003841758 | ||
| 035 | |a (SPR)s00296-009-1040-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malhan, Simten |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Annual costs of rheumatoid arthritis in Turkey |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer-Verlag 2009 | ||
| 520 | |a Abstract Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution(SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as €2,669.14 patient/year. Outpatient costs were found to be €240.40. Routine tests during the year were calculated as €98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was €87.76. €2,238 was determined as being paid per year for medication alone (including anti-TNF) and €4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies. | ||
| 650 | 4 | |a Rheumatoid arthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Annual cost |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Turkey |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Akbulut, Lale Aktekın |4 aut | |
| 700 | 1 | |a Bodur, Hatice |4 aut | |
| 700 | 1 | |a Tulunay, Cankat F. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 30(2009), 5 vom: 07. Juli, Seite 637-641 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2009 |g number:5 |g day:07 |g month:07 |g pages:637-641 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-009-1040-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2009 |e 5 |b 07 |c 07 |h 637-641 | ||